The impact of frailty on prescribing patterns and medication tolerability in interstitial lung disease
<title>Extract</title> Pharmacologic treatment for interstitial lung disease (ILD) is often poorly tolerated with at least 20% of patients experiencing adverse effects requiring treatment discontinuation [1–4]. Nearly half of patients with fibrotic ILD are frail or vulnerable and have worse survival compared to fit patients [5]. In this study, we aimed to determine whether prescribing practices for ILD treatments and medication tolerability differ based on a patient's frailty, potentially explaining worse outcomes among frail individuals [5].
Authors
- H. Manganas
- Veronica Marcoux (ORCID: https://orcid.org/0000-0001-5890-3227)
- Alyson W. Wong (ORCID: https://orcid.org/0000-0003-4910-1948)
- Sabina A. Guler (ORCID: https://orcid.org/0000-0002-9833-5911)
- Christopher J. Ryerson (ORCID: https://orcid.org/0000-0003-1049-393X)
- Kerri A. Johannson (ORCID: https://orcid.org/0000-0003-1205-5511)
- Deborah Assayag (ORCID: https://orcid.org/0000-0002-2497-9984)
- Jolene H. Fisher
- Martin Kolb (ORCID: https://orcid.org/0000-0003-3837-1467)
- Daniel-Costin Marinescu
Institutions
- University of Bern (CH)
- Providence Health Care (CA)
- University of British Columbia (CA)
- University of Calgary (CA)
- University of Toronto (CA)
- University Hospital of Bern (CH)
- St. Paul's Hospital (CA)
- University of Saskatchewan (CA)
- Centre Hospitalier de l’Université de Montréal (CA)
- Institute for Respiratory Health (AU)
- McGill University (CA)
- McMaster University (CA)
Publication Details
- Journal
- European Respiratory Journal
- Published
- 2025-10-23
- DOI
- https://doi.org/10.1183/13993003.01533-2025
- Citations
- 2
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 3.04